Clinical trials: Locally Advanced Cervical Carcinoma
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that…
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
- Trial name
- FOCUS-01 (NCT07454642)
- Testing
- AVA6103
- Where
- 7 sites in United States
- Volunteers
- 174 people
- Sponsor
- Avacta Life Sciences Ltd
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Nasopharyngeal Carcinoma (NPC)
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
This Phase II study is a clinical trial exploring the efficacy and safety of BL-B01D1 with or without PD-1 monoclonal antibody in patients with high-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07797881
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC)
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
- Conditions
- Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07390838
- Testing
- SH009
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2…
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
- Trial name
- IL Believe (NCT05081609)
- Testing
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 320 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors Cancer
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone and in combination with a PD-1 target agent or with a VEGF TKI.
- Trial name
- NCT04417465
- Testing
- ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
- Where
- 17 sites in United States, France and 5 more
- Volunteers
- 101 people
- Sponsor
- AbbVie
Cervical Cancer
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a dose-escalation, single arm, open label study in 10 patients to evaluate the safety and tolerability of KRC 01.
- Trial name
- NCT05570422
- Testing
- KRC-01, External Beam Radiation Therapy, cisplatin
- Where
- 4 sites in India, Thailand and 1 more
- Volunteers
- 70 people
- Sponsor
- Kortuc, Inc.
Squamous Cell Carcinoma of Head and Neck
Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
Primary Objective: To evaluate the overall response rate (including complete response and partial response) of subjects treated with combination therapy docetaxel and cisplatin followed by the chemoradiotherapy in patients with…
- Trial name
- DECIDE (NCT02061631)
- Testing
- Cisplatin, DOCETAXEL XRP6976, Dexamethasone
- Where
- Pakistan
- Volunteers
- 35 people
- Sponsor
- Sanofi
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis
Advanced Cancer, Cervical Cancer
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent…
- Trial name
- NCT03104699
- Testing
- AGEN2034
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 211 people
- Sponsor
- Agenus Inc.
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo…
- Trial name
- MIT-001 (NCT04651634)
- Testing
- MIT-001 plus CCRT
- Where
- 16 sites in United States, South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
Metastatic Cancer, Solid Tumor
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by…
- Trial name
- NCT04641871
- Testing
- Sym021, Sym022, Sym023
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 78 people
- Sponsor
- Symphogen A/S
Squamous Cell Carcinoma of Head and Neck
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
This is a study comparing the activity of lapatinib versus placebo followed by chemoradiation. This study is designed to explore the effects of lapatinib monotherapy on apoptosis/necrosis, in pre-treatment and post-treatment…
- Trial name
- NCT00371566
- Testing
- Lapatinib oral tablets
- Where
- 9 sites in France, Greece and 3 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Head and Neck Squamous Cell Carcinoma, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232524
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Squamous Cell Cancer, Cancer of Head and Neck
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination
- Trial name
- NCT00255476
- Testing
- gefitinib, cisplatin, 5-flourouracil
- Where
- United Kingdom
- Volunteers
- 64 people
- Sponsor
- AstraZeneca